PCSK9 Inhibitors: No Short-term Diabetes Risk in Meta-analysis

Share this post

Treatment with PCSK9 inhibitors was associated with a small increase in glycemia and HBA1c, but not new or worsening diabetes, at least at 42 weeks of treatment, a meta-analysis suggests.
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply